Erste Asset Management’s Vaxcyte PCVX Stock Holding History

Erste Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-33,600	Closed	-$2.65M	–	562
2024 Q2	$2.65M	Hold	33,600	–	–	0.04%	282
2024 Q1	$2.3M	Hold	33,600	–	–	0.03%	289
2023 Q4	$2.13M	Buy	33,600 +4,600	+16%	+$239K	0.03%	292
2023 Q3	$1.46M	Hold	29,000	–	–	0.03%	304
2023 Q2	$1.41M	Hold	29,000	–	–	0.02%	322
2023 Q1	$1.05M	Hold	29,000	–	–	0.02%	359
2022 Q4	$1.38M	Buy	29,000 +14,800	+104%	+$581K	0.03%	312
2022 Q3	$352K	Hold	14,200	–	–	0.01%	457
2022 Q2	$294K	Hold	14,200	–	–	0.01%	481
2022 Q1	$342K	Hold	14,200	–	–	0.01%	466
2021 Q4	$341K	Hold	14,200	–	–	0.01%	464
2021 Q3	$366K	Hold	14,200	–	–	0.01%	443
2021 Q2	$321K	Hold	14,200	–	–	0.01%	447
2021 Q1	$265K	Hold	14,200	–	–	0.01%	435
2020 Q4	$398K	Buy	+14,200	New	+$528K	0.01%	409

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Erste Asset Management's PCVX Position: Q3 2024 in Review

Erste Asset Management sold out of Vaxcyte (PCVX) in Q3 2024, closing a stake of 33,600 shares — an estimated $2.65M sold.

Erste Asset Management first reported a position in PCVX in Q4 2020 and held it in 15 quarters. The position peaked at $2.65M in Q2 2024. 328 funds tracked by Wall St. Rank hold PCVX as of Q3 2024.

Erste Asset Management reported no remaining Vaxcyte position as of Q3 2024 after selling out during the quarter.
Erste Asset Management sold 33,600 Vaxcyte shares in Q3 2024, an estimated $2.65M.
Erste Asset Management first reported a position in Vaxcyte in Q4 2020 and held it in 15 quarters.
Erste Asset Management's Vaxcyte position peaked at $2.65M in Q2 2024.
328 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2024.

Based on Erste Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.